We are pleased to announce that Torben Jørgensen has joined ArgusEye as the new Chairman of the Board – a valuable asset to the company as we continue to innovate and expand.

With decades of experience in the biopharmaceutical and life science industry, Torben brings a rare combination of strategic insights and financial acumen. Throughout his career, he has consistently delivered transformative results – scaling organizations, driving innovation, and unlocking long-term value through focused leadership and collaboration.

A hallmark of Torben’s leadership style is his hands-on approach. He believes that being actively involved and present where day-to-day operations take place is essential to staying aligned with teams and anticipating future needs. His ability to remain grounded in the operational core while maintaining a forward-looking perspective has been central to his success.

My leadership philosophy is grounded in years of experience and shaped by my Danish roots. I prioritize transparency and open dialogue, and I like being present in the ‘engine room’. It allows me to engage with the team on a more detailed level and ensure we’re aligned and moving decisively toward our goals.

Over the course of his career, Torben has developed an ability to balance big-picture thinking with attention to operational detail. He has led organizations through significant growth, global expansion, and the development of sustainable business models. Equally important, he has developed a deep understanding of the scientific and commercial forces shaping the biopharma landscape – insights that will be invaluable as ArgusEye accelerates its own development plan.

I am drawn to companies with a strong emphasis on commercialization and internationalization, areas that have defined my career over the past 40 years. Being part of a scale-up again is energizing. With my experience, I believe I can add value across multiple dimensions. At this stage of growth that ArgusEye is in, there are numerous challenges to navigate, and I’m confident in my ability to help the team stay focused, prioritize effectively, and make the most of available resources.

Torben also brings a broad and current perspective on the evolving biopharma and life science landscape, including emerging trends and challenges. His industry expertise will support ArgusEye’s ambition to become a global leader in enabling technologies for bioprocessing.

I see significant potential for ArgusEye’s to establish a strong foothold in supporting the biopharmaceutical industry, particularly by helping big pharma companies, CDMOs, CROs and CMOs streamline their workflows. Enabling these organizations to operate more efficiently and deliver results faster is critical to accelerating drug development, and that’s exactly where ArgusEye can make a meaningful impact.

We are thrilled to welcome Torben to our board. His guidance will be invaluable in helping us strengthen our position in the biopharmaceutical space, where our vision is to transform the development and production of biopharmaceuticals.